AKAnders G. Kjærgaard

Anders G. Kjærgaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anders G. Kjærgaard has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The use of the soluble adhesion molecules sE‐selectin, sICAM‐1, sVCAM‐1, sPECAM‐1 and their ligands CD11a and CD49d as diagnostic and prognostic biomarkers in septic and critically ill non‐septic ICU patients

    by Anders G. Kjærgaard, Anders Dige, Jeppe S. Nielsen, Else Tønnesen, Jan Krog

    Endothelial activation is pivotal in the development and escalation of sepsis. Central to endothelial activation is the endothelial up‐regulation of cellular adhesion molecules (CAMs) including E‐selectin, ICAM‐1, VCAM‐1, and PECAM‐1. Shed CAMs are also found in circulating soluble forms (sCAMs). We investigated whether sCAMs can be used as biomarkers for the differentiation between septic and non‐septic patients. Furthermore, we investigated lymphocyte and monocyte expression of LFA‐1 (CD11a/CD18) and VLA‐4 (CD49d/CD29) ligands for ICAM‐1 and VCAM‐1, respectively. Twenty‐one septic and 15 critically ill non‐septic patients were included. All patients had an APACHE II score above 13 at ICU admission. Fifteen healthy volunteers served as controls. Flow cytometry was used to estimate levels of sE‐selectin, sICAM‐1, sVCAM‐1, sPECAM‐1, and the cellular expression of CD11a and CD49d. Levels of sE‐selectin, sICAM‐1 and sPECAM‐1 were higher in the septic patients compared with the non‐septic patients and controls at admission and during the observation period. Lymphocyte and monocyte expression of CD11a and CD49d was suppressed or unaltered in the septic patients compared with the non‐septic patients and controls. Levels of sE‐selectin, sICAM‐1, and sPECAM‐1 were able to discriminate between septic and non‐septic patients, indicating that sCAMs may be potential diagnostic biomarkers of sepsis.


  • Open Access

    Monocyte Expression and Soluble Levels of the Haemoglobin Receptor (CD163/sCD163) and the Mannose Receptor (MR/sMR) in Septic and Critically Ill Non-Septic ICU Patients

    by Anders G. Kjærgaard, Sidsel Rødgaard-Hansen, Anders Dige, Jan Krog, Holger J. Møller, Else Tønnesen

    The diagnosis of sepsis is challenging and there is an unmet need for sensitive and specific diagnostic and prognostic biomarkers. Following activation of macrophages and monocytes, the haptoglobin-haemoglobin receptor (CD163) and the mannose receptor (MR) are shed into the circulation (sCD163 and sMR). We investigated monocyte expression of CD163 and MR, and levels of sCD163 and sMR in septic and non-septic patients, and in healthy controls. We hypothesised that these receptors are elevated during sepsis and can be used diagnostic and prognostic. Twenty-one patients with severe sepsis or septic shock and 15 critically ill non-septic patients were included in this prospective observational study at three ICUs at Aarhus University Hospital and Randers Regional Hospital, Denmark. Fifteen age- and gender-matched healthy volunteers served as controls. Levels of sCD163 and sMR were measured using a sandwich ELISA and monocyte expression of CD163 and MR was evaluated by flow cytometry during the first four days of ICU stay. The diagnostic and prognostic values of the receptors were assessed using AUROC curves. At ICU admission and during the observation period, monocyte expression of CD163 and levels of sCD163 and sMR were significantly higher in septic patients compared with non-septic patients and healthy controls (pp = 0.02) and during the observation period (p = 0.006). The prognostic value of monocyte-bound CD163 estimated by AUROC at ICU admission was 0.82. The macrophage-specific markers CD163, sCD163, and sMR are increased in septic patients. Particularly sMR is a promising new biomarker of sepsis.


  • Open Access

    Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis

    by Tue W Kragstrup, Babak Jalilian, Malene Hvid, Anders Kjærgaard, René Østgård, Berit Schiøttz-Christensen, Anne G Jurik, William H Robinson, Thomas Vorup-Jensen, Bent Deleuran

    Introduction: Spondyloarthritis (SpA) comprises a group of diseases often associated with HLA-B27 and characterized by inflammation of the entheses and joints of the axial skeleton. The inflammatory process in SpA is presumably driven by innate immune cells but is still poorly understood. Thus, new tools for monitoring and treating inflammation are needed. The family of CD18 integrins is pivotal in guiding leukocytes to sites of inflammation, and CD18 hypomorphic mice develop a disease resembling SpA. Previously, we demonstrated that altered soluble CD18 (sCD18) complexes in the blood and synovial fluid of patients with arthritis have anti-inflammatory functions. Here, we study the mechanisms for these alterations and their association with SpA disease activity. Methods: Plasma levels of sCD18 in a study population with 84 patients with SpA and matched healthy controls were analyzed with a time-resolved immunoflourometric assay (TRIFMA). Binding of sCD18 to endothelial cells and fibroblast-like synoviocytes (FLSs) was studied with confocal microscopy. Shedding of CD18 from peripheral blood mononuclear cells (PBMCs) was studied with flow cytometry and TRIFMA. Results: Plasma levels of sCD18 were decreased in patients with SpA compared with healthy volunteers (P P P P P P P in vitro. First, sCD18 in plasma adhered to inflammation-induced intercellular adhesion molecule 1 (ICAM-1) on endothelial cells and FLS, indicating increased consumption. Second, CD18 shedding from SpA PBMCs correlated inversely with the BASDAI (P ++ CD16+ monocytes, supporting the view that alterations in innate immunity can regulate the inflammatory processes in SpA. Conclusions: Taken together, the failure of patients with SpA to maintain adequate sCD18 levels may reflect insufficient CD18 shedding from monocytes to counterbalance the capture of sCD18 complexes to inflammation-induced ICAM-1. This could increase the availability of ICAM-1 molecules on the endothelium and in the synovium, facilitating leukocyte migration to the entheses and joints and aggregating disease activity.


  • Open Access

    Soluble Adhesion Molecules Correlate with Surface Expression in an In Vitro Model of Endothelial Activation

    by Anders G. Kjærgaard, Anders Dige, Jan Krog, Else Tønnesen, Lise Wogensen

    Endothelial activation is a pivotal event in the development and progression of inflammation. Central to endothelial activation is the up‐regulation of cellular adhesion molecules (CAMs) including E‐selectin (CD62E), ICAM‐1 (CD54), VCAM‐1 (CD106) and PECAM‐1 (CD31). These CAMs are also found in soluble forms (sCAMs). In this in vitro study of endothelial activation, we examined whether the levels of sCAMs correlate with the endothelial surface expression of CAMs in a dose‐dependent and time‐dependent manner. Such a correlation would support the use of sCAMs as surrogate markers for endothelial activation in inflammatory conditions. Human umbilical vein endothelial cells (HUVEC) were cultured with various concentrations of TNF‐α for 8 hr and at a fixed concentration of TNF‐α for various durations. The levels of soluble and surface‐bound E‐selectin, ICAM‐1, VCAM‐1 and PECAM‐1 were quantified by flow cytometry. TNF‐α stimulation increased CAM and sCAM expression in a dose‐dependent and time‐dependent manner. There was a significant positive correlation between the levels of ICAM‐1 and sICAM‐1 and between the levels of VCAM and sVCAM‐1 in both the dose–response and time–response experiments. A positive correlation between the levels of E‐selectin and sE‐selectin was observed in the time–response experiment. This study supports the use of sCAMs as potential biomarkers of endothelial activation. In particular, the use of sICAM‐1, sVCAM‐1 and sE‐selectin seems promising.